enGene Holdings ENGN 深 滬
已收盤 08-07 16:00:00 美东时间
1.80
0.000
0.00%
華盛通- 最 高1.8383
- 今 開1.81
- 成交量 35.16万股
- 最 低 1.785
- 昨 收 1.80
- 總市值 1.21亿
- 52周最高 12.25
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.40
- 委 比 -63.44%
- 總股本 6698.95万
- 歷史最高 43.00
- 量 比 0.91
- 振 幅 2.96%
- 歷史最低 1.40
- 每 手 1
- 風險率 2.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多enGene Highlights Progress of Lead Bladder Cancer Therapy
enGene Holdings ( ($ENGN) ) has provided an update. On July 17, 2026, enGene Th...
07-18 05:34
Morgan Stanley Downgrades enGene Therapeutics to Underweight
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.
06-18 18:48
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS slashed the price target for Sunrun Inc. (NASDAQ:RUN) from $23 to $20. UBS analyst Jon Windham maintained ...
06-16 20:26
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.
06-16 18:19
enGene Holdings GAAP EPS of $0.43
enGene Holdings press release (ENGN): Q2 GAAP EPS of $0.43. As of April 30, 2026, cash, cash equivalents and marketable securities were $285.2 million providing significant operational flexibility. To...
06-15 22:12
enGene Restructures, Cuts Workforce to Advance Bladder Therapy
enGene Holdings ( ($ENGN) ) has provided an announcement. On June 15, 2026, enG...
06-15 21:54
enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 15.69 percent increase over losses of $(0.51) per share from the same period last year.
06-15 21:06
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Why Is enGene Therapeutics Stock Falling Friday?
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
05-08 23:34
